CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 1,304 enrolled
Drug / intervention
Vonoprazandrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03214198
NCT03214198N/ACompleted

Special Drug Use Surveillance of Takecab Tablets for "Prevention of Recurrence of Gastric/Duodenal Ulcer in Patients Receiving Non-steroidal Anti-inflammatory Drugs: Long-term Use"

Takeda·observational·Posted Jul 11, 2017·Updated Jun 7, 2023

In Brief

An observational study evaluating Vonoprazan for A History of Gastric or Duodenal Ulcers. Completed, enrolled 1,304 participants across 1 site.

Detailed Summary

The purpose of this study is to investigate the safety and efficacy of long-term administration of Vonoprazan tablets (Takecab tablets) for up to 12 months in the routine clinical setting in patients receiving non-steroidal anti-inflammatory drugs (NSAIDs).

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesJapan
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedJul 11, 2017
Enrollment StartSep 1, 2016
Primary CompletionApr 30, 2020
TodayJul 2, 2026
Enrollment to primary: 3.7 yearsPosted 9.0 years ago

Interventions

Vonoprazandrug

Vonoprazan tablets